Take note Tomorrow: Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease July 31, 9AM
Presentation title: Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with MCI or mild Alzheimer’s dementia
Presenter: Eric Siemers, MD
Featured Research Session: Glial biomarkers and Alzheimer’s disease therapeutics
Date: Wednesday July 31st, 2024. 9:00 AM EST.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment